You are here

  • Home
  • Archive
  • Volume 11, Issue 7
  • Correction: Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

https://doi.org/10.1136/jitc-2023-006871corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Altan M, Wang Y, Song J, et al. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J ImmunoTher of Cancer 2023;11: e006871. doi: 10.1136/jitc-2023-006871

    This article has been corrected since it was first published online. The author Xiuning Le was incorrectly listed as Xiuning Lee.